GLP-1 Digest Podcast

1. Episode · Aug 2, 2026

   How Shotsy Grew to 350,000 Monthly Active GLP-1 Users, Ep. 9 with Aja Beckett (opens the original)

   Episode notes · Neutral tone

   Read excerpt

   Shotsy’s growth has been explosive—and it has been powered largely by its users. The app now has 350,000 monthly active users. Roughly one-third pay, while around two-thirds of new users arrive organically through word of mouth, community posts and app-store discovery. And it does not prescribe or dispense a single GLP-1. I spoke with founder Aja Beckett about how Shotsy turned product utility into distribution—and built a companion app that remains useful from the first dose through maintenance

   Feedback

2. Episode · Jul 8, 2026

   Can AI Stop GLP-1 Patients From Churning? Ep. 8 with Dr. Paul Sacher (opens the original)

   Episode notes

   Read excerpt

   The economics of DTC GLP-1 care are getting harder. Customer acquisition costs keeps rising, price is getting pushed down, and more patients are willing to switch provider for the cheapest pen. That leaves DTC companies with the worst possible equation: lower gross profit per month and a customer base full of switchers who may not stay long enough to pay back acquisition. In this episode, I speak with Dr. Paul Sacher about where AI can actually show up on the GLP-1 profit and loss statement. Pau

   Feedback

Last 90 days. Choose a month to open its work.

Named in the text we hold. One piece can cover several.

Not enough subject data for this period yet.

No verified audience measurement yet.